DUBLIN–(BUSINESS WIRE)–The “Global Generic Drugs Market 2023-2027” report has been added to ResearchAndMarkets.com’s offering.
The generic drugs market is poised to grow by $176.25 bn during 2023-2027, accelerating at a CAGR of 7.11% during the forecast period. The report on the generic drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by low-cost alternatives, increased outsourcing of drug discovery and development, and rising drug patent expirations.
The generic drugs market is segmented as below:
By Route Of Administration
- Oral
- Injectables
- Topical
- Inhalers
By Type
- Small-molecule generics
- Biosimilars
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the advent of RPA as one of the prime reasons driving the generic drugs market growth during the next few years. Also, rising m and a and hospital-owned generics will lead to sizable demand in the market.
The report on the generic drugs market covers the following areas:
- Generic drugs market sizing
- Generic drugs market forecast
- Generic drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading generic drugs market vendors that include Abbott Laboratories, Amgen Inc., Aurobindo Pharma Ltd., Baxter International Inc., Biocon Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin Ltd., Cadila Pharmaceuticals Ltd., and Cipla Ltd. Also, the generic drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Companies Mentioned
- Abbott Laboratories
- Amgen Inc.
- Aurobindo Pharma Ltd.
- Baxter International Inc.
- Biocon Ltd.
- Dr Reddys Laboratories Ltd.
- Eli Lilly and Co.
- Endo International Plc
- Fresenius SE and Co. KGaA
- GlaxoSmithKline Plc
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Sun Pharmaceutical Industries Ltd.
- Lupin Ltd.
- Cadila Pharmaceuticals Ltd.
- Cipla Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/ia54mf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900